[1]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74-79.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
　Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):74-79.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
点击复制

多巴胺转运体PET显像剂11C-Altropane的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第1期
页码:
74-79
栏目:
综述
出版日期:
2018-03-20

文章信息/Info

Title:
Progress of dopamine transporter PET imaging agent 11C-Altropane
作者:
于江;  段玉清;  毕常芬;  李祎亮
300192 天津, 北京协和医学院中国医学科学院放射医学研究所, 天津市放射医学与分子核医学重点实验室
Author(s):
Yu Jiang;  Duan Yuqing;  Bi Changfen;  Li Yiliang
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Science, Peking Union Medical College, Tianjin 300192, China
关键词:
多巴胺质膜转运蛋白质类; Altropane; 帕金森病; 正电子发射断层显像术
Keywords:
Dopamine plasma membrane transport proteins; Altropane; Parkinson disease; Positron-emission tomography
DOI:
10.3760/cma.j.issn.1673-4114.2018.01.014
摘要:
帕金森病（PD）是一种慢性进行性神经系统变性疾病，患者黑质纹状体多巴胺能神经元的变性脱失会伴随有突触前膜多巴胺转运蛋白（DAT）数量及功能的明显下降。DAT显像剂11C-Altropane可与DAT特异性结合，且比同类药物吸收快、具有更高的亲和力，能直接、灵敏地反映突触前多巴胺能神经元的变化，是PD早期诊断的最佳手段。笔者介绍了PD诊断的现状、PET显像剂的原理及发展过程、11C-Altropane的合成及其作为PET显像剂在临床研究中的应用。
Abstract:
In patients with Parkinson’s disease(PD), a chronic progressive neurological degeneration order, the degeneration and loss of dopaminergic neurons in the substantia nigra is generally associated with the significant decrease in the number and disrupted function of dopamine transporters(DATs) in the presynaptic membrane. 11C-Altropane, a DAT-imaging agent, can specifically binds with DAT and directly reflects the changes in presynaptic dopaminergic neuron. In this paper, the synthesis of 11C-Altropane and its application as a PET imaging agent in clinical research were reviewed.

参考文献/References:

[1] Wang J, Zuo CT, Jiang YP, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages[J]. J Neurol, 2007, 254(2):185-190. DOI:10.1007/s00415-006-0322-9.
[2] Ma Y, Dhawan V, Mentis M, et al. Parametric mapping of[18F]FPCIT binding in early stage Parkinson’s disease:a PET study[J]. Synapse, 2002, 45(2):125-133. DOI:10.1002/syn.10090.
[3] 许靖, 李肖红, 秦永德, 等. 帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J]. 国际放射医学核医学杂志, 2016, 40(5):338-344. DOI:10.3760/cma.j.issn.1673-4114. 2016.05.003. Xu J, Li XH, Qin YD, et al. Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J]. Int J Radiat Med Nucl Med, 2016, 40(5):338-344.
[4] Jankovic J. Parkinson’s disease:clinical features and diagnosis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(4):368-376. DOI:10.1136/jnnp.2007.131045.
[5] Morón JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter:evidence from knock-out mouse lines[J]. J Neurosci, 2002, 22(2):389-395.
[6] Thobois S, Jahanshahi M, Pinto S, et al. PET and SPECT functional imaging studies in Parkinsonian syndromes:from the lesion to its consequences[J]. Neuroimage, 2004, 23(1):1-16. DOI:10.1016/j.neuroimage.2004.04.039.
[7] 李英华, 关锋, 代玉银, 等. 正电子放射性分子显像剂诊断帕金森氏病的研究进展[J]. 核技术, 2012, 35(3):211-215. Li YH, Guan F, Dai YY, et al. Positron radioactive molecular imaging agents for early diagnosis of Parkinson’s disease[J]. Nucl Tech, 2012, 35(3):211-215.
[8] Huang T, Wang H, Tang G, et al. The influence of residual nor-β-CFT in 11C CFT injection on the Parkinson disease diagnosis:a 11C CFT PET study[J]. Clin Nucl Med, 2012, 37(8):743-747. DOI:10.1097/RLU.0b013e31824c5fae.
[9] Hung JC. Bringing new PET drugs to clinical practice-a regulatory perspective[J]. Theranostics, 2013, 3(11):885-893. DOI:10.7150/thno.5513.
[10] Zhu L, Ploessl K, Kung HF. Chemistry. expanding the scope of fluorine tags for PET imaging[J]. Science, 2013, 342(6157):429-430. DOI:10.1126/science.1245011.
[11] 乔晋萍, 乔洪文, 武仙英, 等. 多巴胺神经系统显像分子探针研究[J]. 生命的化学, 2014, 34(2):154-165. DOI:10.13488/j.smhx.20140204. Qiao JP, Qiao HW, Wu XY, et al. Recent advances in PET tracers for imaging of the dopaminergic system[J]. Chem Life, 2014, 34(2):154-165.
[12] 甘红梅, 乔晋萍, 孔爱英, 等. 正电子放射性显像剂代谢及其研究方法进展[J]. 国际放射医学核医学杂志, 2010, 34(2):65-71. DOI:10.3760/cma.j.issn.1673-4114.2010.02.001. Gan HM, Qiao JP, Kong AY, et al. The progress on researching method and metabolism of positron radiopharmaceutical[J]. Int J Radiat Med Nucl Med, 2010, 34(2):65-71.
[13] Quincoces G, Pe?uelas I, Valero M, et al. Simple automated system for simultaneous production of 11C-labeled tracers by solid supported methylation[J]. Appl Radiat Isot, 2006, 64(7):808-811. DOI:10.1016/j.apradiso.2006.03.001.
[14] Elmaleh DR, Fischman AJ, Shoup TM, et al. Preparation and biological evaluation of iodine-125-IACFT:a selective SPECT agent for imaging dopamine transporter sites[J]. J Nucl Med, 1996, 37(7):1197-1202.
[15] Fischman AJ, Bonab AA, Babich JW, et al.[11C, 127I] Altropane:a highly selective ligand for PET imaging of dopamine transporter sites[J]. Synapse, 2001, 39(4):332-342. DOI:10.1002/1098-2396(20010315)39:4<332::AID-SYN1017>3.0.CO;2-X.
[16] Dutta AK, Zhang S, Kolhatkar R, et al. Dopamine transporter as target for drug development of cocaine dependence medications[J]. Eur J Pharmacol, 2003, 479(1/3):93-106. DOI:10.1016/j.ejphar.2003.08.060.
[17] 张锦明, 田嘉禾, 郭喆, 等. 在线自动化制备多巴胺转运蛋白显像剂11C-β-CFT[J]. 中华核医学杂志, 2005, 25(3):142-145. DOI:10.3760/cma.j.issn.2095-2848.2005.03.006. Zhang JM, Tian JH, Guo Z, et al. Automated on-line preparation of 11C-β-CFT, a dopamine transporter imaging agent[J]. Chin J Nucl Med, 2005, 25(3):142-145.
[18] Rinne JO, Bergman J, Ruottinen H, et al. Striatal uptake of a novel PET ligand,[18F]beta-CFT, is reduced in early Parkinson’s disease[J]. Synapse, 1999, 31(2):119-124. DOI:10.1002/(SICI) 1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O.
[19] Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, and equilibrium analyses of in vivo[123I] β-CIT binding to dopamine transporters in healthy human subjects[J]. J Cereb Blood Flow Metab, 1994, 14(6):982-994. DOI:10.1038/jcbfm.1994.131.
[20] Djaldetti R, Treves TA, Ziv I, et al. Use of a single[123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease[J]. Neurol Sci, 2009, 30(4):301-305. DOI:10.1007/s10072-009-0100-4.
[21] Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT[J]. J Nucl Med, 1996, 37(7):1129-1133.
[22] Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:I. Dopamine transporter binding in primate brain[J]. Synapse, 1998, 29(2):93-104. DOI:10.1002/(SICI)1098-2396(199806)29:2<93::AID-SYN1>3.0.CO; 2-5.
[23] Madras BK, Gracz LM, Meltzer PC, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:II. Distritution to dopamine-rich region of primate brain[J]. Synapse, 1998, 29(2):105-115. DOI:10.1002/(SICI)1098-2396(199806)29:2<105:AID-SYN2>3.0.CO; 2-B.
[24] Madras BK, Gracz LM, Fahey MA, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons:Ⅲ. Human dopamine transporter in postmortem normal and Parkinson’s diseased brain[J]. Synapse, 1998, 29(2):116-127. DOI:10.1002/(SICI)1098-2396(199806)29:2<116:AID-SYN3>3.0.CO;2-A.
[25] Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson’s disease by SPECT with altropane:a selective ligand for dopamine transporters[J]. Synapse, 1998, 29(2):128-141. DOI:10.1002/(SICI)1098-2396(199806)29:2<128:AID-SYN4>3.0.CO; 2-9.
[26] Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using[11C] altropane and[11C] raclopride[J]. Biol Psychiatry, 2010, 68(10):964-970. DOI:10.1016/j.biopsych.2010.08.026.
[27] Spencer TJ, Biederman J, Faraone SV, et al. Functional genomics of attention-deficit/hyperactivity disorder(ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects[J]. Biol Psychiatry, 2013, 74(2):84-89. DOI:10.1016/j.biopsych.2012.11.010.
[28] Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases:an 11C altropane positron emission tomography study[J/OL]. Alzheimers Res Ther, 2014, 6(5-8):52[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245149. DOI:10.1186/s13195-014-0052-7.
[29] Rieckmann A, Gomperts SN, Johnson KA, et al. Putamen-midbrain functional connectivity is related to striatal dopamine transporter availability in patients with Lewy body diseases[J/OL]. Neuroimage Clin, 2015, 8:554-559[2017-10-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484547. DOI:10.1016/j. nicl. 2015. 06.001.
[30] Rieckmann A, Hedden T, Younger AP, et al. Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity[J]. Hum Brain Mapp, 2016, 37(2):621-631. DOI:10.1002/hbm.23054.
[31] Elsinga PH, Hatano K, Ishiwata K. PET tracers for imaging of the dopaminergic system[J]. Curr Med Chem, 2006, 13(18):2139-2153. DOI:10.2174/092986706777935258.
[32] 李海峰, 张晓军, 张锦明, 等. 多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J]. 国际放射医学核医学杂志, 2016, 40(3):218-224. DOI:10.3760/cma.j.issn.1673-4114. 2016.03.011. Li HF, Zhang XJ, Zhang JM, et al. Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J]. Int J Radiat Med Nucl Med, 2016, 40(3):218-224.

相似文献/References:

[1]柴黎明,杨小丰,王爽,等.多巴胺转运体显像剂11C-CFT和18F-CFT及其临床应用进展[J].国际放射医学核医学杂志,2009,33(4):232.[doi:10.3760/cma.j.issn.1673-4114.2009.04.012]
　CHAI Li-ming,YANG Xiao-feng,WANG Shuang,et al.Dopamine transporter imaging agent 11C-CFT and 18F-CFT and its clinical application development[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):232.[doi:10.3760/cma.j.issn.1673-4114.2009.04.012]
[2]朱毓华,鲁佳荧,张慧玮,等.FBP和OSEM对正常人脑内多巴胺转运体分布半定量值影响的研究[J].国际放射医学核医学杂志,2018,(5):409.[doi:10.3760/cma.j.issn.1673-4114.2018.05.004]
　Zhu Yuhua,Lu Jiaying,Zhang Huiwei,et al.Effects of the different PET image reconstruction methods on distribution of dopamine transporter in healthy human brain[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):409.[doi:10.3760/cma.j.issn.1673-4114.2018.05.004]

备注/Memo

备注/Memo:
收稿日期:2017-10-07。
基金项目:中国医学科学院医学与健康科技创新工程项目（2016-I2M-3-022、2017-I2M-3-019）
通讯作者:李祎亮,Email:liyiliang75@163.com
更新日期/Last Update: 2018-03-20